BioCentury
ARTICLE | Politics, Policy & Law

Carl Icahn & other card sharks

February 19, 2002 8:00 AM UTC

For those who missed Friday's episode, a white knight appeared and stated his intention to sweep up the bride and carry her off into the sunset . . .

The ImClone Systems Inc. saga continued with a cameo appearance by financier and corporate raider Carl Icahn, who announced his intention to acquire up to $500 million of IMCL stock, IMCL's adoption of a poison pill, more leaked information about alleged deficiencies in the design of IMCL's Phase II trial of Erbitux in colorectal cancer, and IMCL's rejection of partner Bristol-Myers Squibb Co.'s demand that the pharma company be given more say in the development of Erbitux (see BioCentury Extra, Tuesday Feb. 12 & Friday Feb. 15). ...